Who are Treatment and prophylaxis's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Reyataz + Epzicom, bictegravir/emtricitabine/tenofovir alafenamide, CAR, dolutegravir/abacavir/lamivudine, AZT+3TC+IDV+RTV, Nevirapine (Viramune).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/treatment-and-prophylaxis.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Treatment and prophylaxis — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment and prophylaxis (Treatment and prophylaxis) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NRTI (nucleoside reverse transcriptase inhibitor). Area: Infectious Disease.

phase 3 NRTI (nucleoside reverse transcriptase inhibitor) Reverse transcriptase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Treatment and prophylaxis (Treatment and prophylaxis) — Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia. This drug works by inhibiting the replication of the human immunodeficiency virus (HIV).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Treatment and prophylaxis TARGET	Treatment and prophylaxis	Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia	phase 3	NRTI (nucleoside reverse transcriptase inhibitor)	Reverse transcriptase
Reyataz + Epzicom	Reyataz + Epzicom	ViiV Healthcare	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
bictegravir/emtricitabine/tenofovir alafenamide	bictegravir/emtricitabine/tenofovir alafenamide	Midland Research Group, Inc.	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
CAR	CAR	ViiV Healthcare	marketed	Antiretroviral combination therapy (INSTI + NNRTI)	HIV integrase and HIV reverse transcriptase
dolutegravir/abacavir/lamivudine	dolutegravir/abacavir/lamivudine	University College Dublin	marketed	Antiretroviral combination (INSTI + NRTIs)	HIV integrase, HIV reverse transcriptase
AZT+3TC+IDV+RTV	AZT+3TC+IDV+RTV	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase; HIV protease
Nevirapine (Viramune)	Nevirapine (Viramune)	Germans Trias i Pujol Hospital	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NRTI (nucleoside reverse transcriptase inhibitor) class)

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Treatment and prophylaxis — Competitive Intelligence Brief. https://druglandscape.com/ci/treatment-and-prophylaxis. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab